Stock Events

Stock Events

Biofrontera 

€2.51
59
+€0.03+1.21% Monday 15:30

Statistics

Day High
2.48
Day Low
2.47
52W High
2.95
52W Low
2.26
Volume
1
Avg. Volume
-
Mkt Cap
37.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.53
-0.36
-0.19
-0.02
Expected EPS
N/A
Actual EPS
N/A

Financials

-25.63%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
36.13MRevenue
-9.26MNet Income

Analyst Ratings

2.28Average Price Target
The highest estimate is 2.28.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B8FK.XETRA. It's not an investment recommendation.
Apple
8
AAPL
NVIDIA
8
NVDA
AMD
8
AMD
Tesla
7
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Davis Select U.S. Equity
DUSA
Mkt Cap0
DUSA Pharmaceuticals, Inc. is a direct competitor in the dermatology space, specifically in photodynamic therapy products, similar to Biofrontera's Ameluz for treating actinic keratosis.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. has a diversified portfolio that includes treatments for various conditions, including skin-related diseases, potentially competing with Biofrontera's dermatological products.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. is a global pharmaceutical company with a broad product line that includes treatments for skin conditions, making it a competitor to Biofrontera.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson offers a wide range of healthcare products, including pharmaceuticals and personal care products for skin health, competing with Biofrontera's dermatological treatments.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie Inc., having acquired Allergan, has strengthened its dermatology portfolio, making it a stronger competitor to Biofrontera in the skin care and treatment market.
Novartis
NVS
Mkt Cap304.1B
Novartis International AG has a significant presence in the dermatology market with products that treat a range of skin conditions, competing with Biofrontera's therapeutic offerings.

About

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Show more...
CEO
Hermann Lübbert
Employees
94
Country
United States
ISIN
DE000A4BGGM7
WKN
000A4BGGM

Listings

XNAS
US
BFRI
MU
DE
B8FK.MU
MU
DE
AI1.MU
STU
DE
AI10.STU

0 Comments

Share your thoughts

FAQ

What is Biofrontera stock price today?▼
The current price of B8FK.XETRA is €2.51 EUR — it has increased by +1.21% in the past 24 hours. Watch Biofrontera stock price performance more closely on the chart.
What is Biofrontera stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Biofrontera stocks are traded under the ticker B8FK.XETRA.
Is Biofrontera stock price growing?▼
B8FK.XETRA stock has risen by +4.58% compared to the previous week, the month change is a -3.46% fall, over the last year Biofrontera has showed a -1.95% decrease.
What is Biofrontera market cap?▼
Today Biofrontera has the market capitalization of 37.28M
When is the next Biofrontera earnings date?▼
Biofrontera is going to release the next earnings report on November 19, 2026.
What were Biofrontera earnings last quarter?▼
B8FK.XETRA earnings for the last quarter are -0.04 EUR per share, whereas the estimation was -0.09 EUR resulting in a +52.38% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Biofrontera revenue for the last year?▼
Biofrontera revenue for the last year amounts to 36.13M EUR.
What is Biofrontera net income for the last year?▼
B8FK.XETRA net income for the last year is -9.26M EUR.
How many employees does Biofrontera have?▼
As of September 08, 2026, the company has 94 employees.
In which sector is Biofrontera located?▼
Biofrontera operates in the Health & Wellness sector.
When did Biofrontera complete a stock split?▼
The last stock split for Biofrontera was on May 14, 2024 with a ratio of 1:21.
Where is Biofrontera headquartered?▼
Biofrontera is headquartered in WOBURN, United States.